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the refractoriness of accessory pathways and reduce the rate 
of pre-excited supraventricular arrhythmias.(9)
Guidelines
2019 saw new European Society of Cardiology guidelines for 
the management of patients with SVT(10) which had previously 
been updated in 2003. However, there was little that was very 
new. The guidelines insisted that ablation was the best initial 
management for most re-entrant atrial and AV junctional 
tachycardia. However, atrial tachycardia occurring after abla-
tion for AF should not be considered for ablation until at least 
3 months after the AF ablation procedure. The guidelines 
stressed that ablation for AV nodal re-entrant tachycardia could 
be achieved in almost all without risk of AV block. An invasive 
EP risk assessment of Wolff-Parkinson-White syndrome was 
recommended, even in patients who are asymptomatic but 
have high-risk occupations or are competitive athletes. The 
guidelines recommend ablation in high risk or symptomatic 
WPW patients, but stop short of recommending ablation of 
all accessory pathways. It is pointed out that SVT may cause 
tachycardia-mediated cardiomyopathy and that ablation may 
not only eliminate the tachycardia but restore ventricular 
function.
There are strong Class III recommendations – “what not to do”, 
mostly related to antiarrhythmic drug therapy (Figure 1).
ATRIAL FIBRILLATION RISK ASSESSMENT AND 
TREATMENT DECISIONS
Various studies have highlighted new developments in the risk 
assessment for the development of AF and its complications, as 
well as the use of the non-vitamin K antagonist oral anticoagu-
lants (NOACs) as thromboprophylaxis.
Risk assessment
Numerous clinical factors associated with incident AF have 
been described,(11) but a simple, practical and reliable approach 
to identifying patients at risk of incident AF is needed.
Clinical factors such as change in body mass index have been 
associated with an increased risk of AF,(12)  as has disordered 
sleep pattern.(13)  Various clinical risk scores for identifying 
incident AF have been described, and as with most clinical 
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INTRODUCTION
During this last year, there has been much progress with regard 
to anticoagulant and ablation therapy for atrial fibrillation (AF). 
Apart from recently issued European Society of Cardiology 
Guidelines for the management of patients with supraventricular 
arrhythmias, there has been little progress in research in this 
field. Ventricular arrhythmias and device therapy have seen 
modest progress.
SUPRAVENTRICULAR TACHYCARDIAS
This year has seen several publications on the ECG diagnosis of 
supraventricular tachycardia (SVT)(1-4) and interest in new con-
sumer-led discovery of supraventricular arrhythmias.(5) EP map-
ping technology has provided better mapping of SVT.(6) There 
has been a surprising interest in new antiarrhythmic drugs for 
SVT, ranging for intranasal etripamil (an L-type calcium anta-
gonist) for termination of SVT(7,8)  and nifekalant to increase 
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scores, all have modest predictive value for identifying high-risk 
patients, and, until recently, there have been complex models 
derived from multivariate analyses. The C2HEST score was 
derived and validated in Asia and has recently been externally 
validated in a French post-stroke cohort and the Danish nation-
wide registries.(14,15)  This would facilitate targeted intensive 
screening for AF, for example, in the post-stroke population 
with AF, where oral anticoagulation (OAC) as secondary pre-
vention is well established. In contrast, two randomised trials in 
embolic stroke of unknown source (ESUS) using NOACs failed 
to show a significant reduction in recurrent stroke, while one 
trial (NAVIGATE-ESUS) showed an excess of bleeds.(16,17)
Screening for AF has attracted much attention, with popula-
tion-based approaches and new technologies.(18)  The Apple 
Watch study investigated if a smartwatch-based irregular pulse 
notification algorithm identified possible AF, and reported 
that among participants who received notification of an irre-
gular pulse, 34% had atrial fibrillation AF on subsequent ECG 
patch readings and 84% of notifications were concordant 
with AF.(19) The Huawei Heart Study also showed the usefulness 
of photoplethysmographic (PPG)-based technology in popu-
lation screening for AF, with the positive predictive value of 
PPG signals being 91.6% and leading to improved anticoagula-
tion use (>80%).(20)
Risk assessment continues to evolve, with availability of new 
data showing stroke risks associated with AF patients with 
hypertrophic cardiomyopathy(21) and imaging-documented sig-
nificant coronary artery lesions.(22)  There has been much 
interest in the use of sophisticated methods such as machine-
learning, even predicting incident AF from a simple 12-lead 
ECG.(23)  More complex risk assessment approaches improve 
AF stroke risk prediction (at least statistically), but need to 
be balanced against simplicity and practical application. For 
now, an independent Patient Cantered Outcome Research 
Institute (PCORI)-sponsored systematic review and evidence 
appraisal identified that among the commonly used risk 
stratification schemes in patients with AF, the CHA2DS2VASc 
and HAS-BLED scores were the best predictors for stroke and 
bleeding risks, respectively.(24)  Bleeding risk prediction only 
focused on modifiable bleeding risk factors is an inferior strategy 
to a formal risk assessment using the HAS-BLED score.(25,26)
Stroke and bleeding risk assessments incorporating biomarkers 
have been proposed based on highly selected anticoagulated 
FIGURE 1: Some “What not to do” recommendations from the 2019 ESC Guidelines on the management of patients 
with supraventricular tachycardia. 
MRAT, macro re-entrant atrial tachycardia. Reproduced with permission from ref.(10) 
Recommendations for the acute management of wide QRS tachycardia in the absence of an estabished diagnosis
Verapamil is not recommended in wide QRS-complex tachycardia of unknown aetiology. III B
Recommendations for the therapy of MRATs
Acute therapy
Propafenone and fl ecainide are not recommended for conversion to sinus rhythm. III B
Recommendations for the therapy of AVRT due to manifest or concealed APs
Chronic therapy
Digoxin, beta-blockers, diltiazem, verapamil and amiodarone are not recommended and are potentially harmful in patients with 
pre-excited AF. III B
Recommendations for the acute therapy of pre-excited AF
Haemodynamically stable patients
Amiodarone (i.v.) is not recommended. III B
Recommendations for the therapy of SVTs in congenital heart disease in adults
Chronic therapy
Sotalol is not recommended as a fi rst-line antiarrhythmic drug as it is related to an increased risk of pro-arrhythmias and mortality. III C
Flecainide and propafenone are not recommended as fi rst-line antiarrhythmic drugs in patients with ventricular dysfunction and 
severe fi brosis. III C
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clinical trial cohorts, but “real-world” studies have not shown 
the usefulness of such schemes. One study showing sequential 
addition of biomarkers did not improve the usefulness of stroke 
and bleeding risk prediction.(27) Also, there are no data across 
the patient pathway, when first diagnosed and non-anti-
coagulated, or on aspirin – and following the initiation of OAC. 
Of note, many risk factors are based on baseline risk assess-
ment, but do not remain static and change with age and inci-
dent risk factors.(25,28)  Thus, AF assessment is not a “one off” 
item and needs to be reassessed at regular intervals, e.g. every 
4 - 6 months.(29)
Non-vitamin K antagonist oral anticoagulants and atrial 
fi brillation management in clinical practice
The NOACs have changed the landscape of stroke prevention 
in AF. These drugs are now the preferred OAC option in most 
guidelines, but challenges remain in their use among high-risk 
subgroups that were under-represented in clinical trials, as well 
as adherence and persistence.
Clinical trial cohorts are selected populations and may be at 
lower risk compared to “real-world” clinical practice data.(30) 
The year also saw the first publications of real-world data 
for edoxaban, which was the fourth NOAC to enter the 
market.(31)  Increasing data for the NOACs in the elderly have 
been published,(32,33)  clearly showing their effectiveness and 
safety even in very elderly subjects, aged ≥80. Additional data 
emphasise the importance of using the appropriate label-
adherent dosing to ensure best outcomes, as well as per-
sistence data with the NOACs, for example, with dabi-
gatran.(34)  One trial, AEGEAN, showed high adherence and 
persistence with apixaban (~90%), but did not show addi-
tional benefit from interventions to improve adherence/
persistence.(35)
Also, studies of NOAC use in extremes of renal function, both 
severe renal impairment and supra-normal renal function are 
important. The latter is pertinent given that all 3 Factor Xa 
inhibitors showed numerically more ischaemic strokes in the 
subgroup with CrCl >95mL/min when compared with warfarin 
in their pivotal trials, although this is not apparent in real-world 
observational data.(36)  In end-stage renal failure, observational 
data show better safety for apixaban over warfarin.(37)
The last year has seen new trials with NOACs in catheter 
ablation (CA) for AF, and in the setting of AF patients presenting 
with an ACS or undergoing PCI/stenting. For CA, an uninter-
rupted NOAC-based strategy appears to be a safer option 
compared to a warfarin-based strategy.(38-40)  In AF/ACS/PCI 
patients, the publication to AUGUSTUS and ENTRUST-AF PCI 
completes the trials of NOACs in this clinical setting.(41,42) 
These trials suggest that when OAC is used, a NOAC-based 
regime or a dual therapy (i.e. OAC plus a P2Y12 inhibitor) is 
associated with less major bleeding.(43) Of the overall throm-
botic or ischaemic outcomes, there is little difference between 
a triple therapy or dual therapy approach, or a NOAC-based 
strategy compared to a warfarin-based strategy. However, a 
dual therapy approach may be associated with an excess of 
stent thrombosis and myocardial ischaemic events, and thus 
patients who are at high risk of such outcomes may merit a 
short period of triple therapy at the start. In stable coronary 
disease, OAC alone is associated with better outcomes com-
pared to dual therapy, in the AFIRE trial.(44)
While the concept of integrated AF management has been 
proposed, its application and implementation in a simple, user-
friendly manner have not been previously validated. Integrated 
care has been associated with reduced mortality and hospi-
talisation.(46) One integrated and holistic approach to AF man-
agement, streamlining the decision-making management 
approaches that would be uniformly applicable across the 
whole AF patient pathway, starting with primary care and 
linking with secondary care (including cardiologist/non-cardi-
ologists), and understandable for the AF patients per se, is the 
ABC (Atrial fibrillation Better Care) pathway: Avoid stroke; 
Better symptom management with patient-centred symptom 
directed decisions on rate or rhythm control; and Cardio-
vascular and risk factor optimisation, including lifestyle 
changes(45)  (Figure  2). The ABC pathway approach has now 
been shown in independent studies to be associated with a 
reduction in mortality, hospitalisation and adverse outcomes, 
as well as reduced healthcare costs, when compared to “non-
ABC” adherent management.(47-50)  The ABC pathway was 
tested in a cluster randomised trial showing improved clinical 
outcomes with an ABC pathway management based on an 
interactive App that included risk assessments, patient decision 
aids, educational materials and dynamic tracking of risk (mAFA-




A number of publications have described AF CA outcomes 
and impact on prognosis. Probably the most eagerly awaited 
was the CABANA study.(51) This multicentre study randomised 
2 204 patients to CA or drug therapy. As designed, intention to 
treat, the study was neutral for CA impacting on the primary 
composite endpoint of death, disabling stroke, serious bleeding, 
or cardiac arrest. This type of study is incredibly difficult to 
recruit for because the clinicians most likely to recruit are seeing 
a patient referred for a CA, so even if they are prepared to 
enter the study, the cross-over rate is likely to be high from 
drug to ablation, as it was in this study (27.5%). When analysing 
by treatment, there was a prognostic benefit, but this subverts 














The cerebral micro-emboli associated with AF CA do not 
appear to have much impact and CA itself may improve cog-
nitive impairment as in the 308 patients studied and followed 
for 1 year.(52)
Most electrophysiologists continue to tell patients that the 
primary goal of AF ablation is quality of life (QOL). The first 
randomised controlled trials (RCT) of AF CA vs. drugs to 
examine QOL as the primary endpoint were published in 
2019 and favoured CA.(53) While this was a small study, with 
155 patients, it does open the way for double-blind RCTs of 
AF CA with QOL as the primary outcome.
The use of cryoablation for AF has accumulated more evi-
dence this year: it is faster than RF CA,(54) associated with lower 
risk of pericardial effusion,(55,56) and has superior outcomes(54,55) 
regardless of centre volume.(57)
Several large registries have published this year. The Swedish 
registry reveals CA procedure complications and death were 
low and that AF, ventricular tachycardia (VT), and premature 
ventricular complex (PVC) CA numbers increased, with AF 
having the highest repeat procedure rate (41%).(58) A European 
registry demonstrated that cryoablation is as effective for 
female patients, but is associated with higher complication 
rates.(59)  The Danish registry confirmed that success rates for 
AFL ablation were 90%, but that AF is a common presentation 
(13%) within the 2 years after.(60) The German Helios registry 
showed that pericardial effusion rates were 0.9% in 21 141 AF 
CA, and were more likely in low volume centres, but only if 
RF was used rather than cryo.(55)
CA of VF storm after myocardial infarction was reported in a 
multicentre study of 110 patients.(61) In-hospital mortality (27%) 
and 2-year follow-up mortality (36%) were high and associated 
with the time taken to perform CA.
A retrospective study of 110 patients demonstrated CA of 
recurrent VT in patients with arrhythmogenic ventricular 
cardiomyopathy, is no more effective than drugs, but is more 
likely to be successful if both epicardial and endocardial 
approaches are used.(62)
New mapping technologies
It is recognised that the primary reasons for failure of CA in 
complex arrhythmia are a lack of understanding of the mecha-
nism. There continues to be huge effort to solve this. This year 
ripple mapping has been used successfully in persistent AF (18 
months 53% vs. 39% conventional),(64) atrial tachycardia,(65) 
and VT in arrhythmogenic right ventricular cardiomyopathy 
(ARVC).(66) Non-contact mapping is returning to clinical practice 
with an observational trial showed good outcomes for persis-
FIGURE 2: Managing atrial fibrillation – Easy as ABC.
Awareness and 









Non-cardiologists, Cardiologists (Non-AF vs. AF)
Primary care Patients with AF
A = Avoid stroke/anticoagulation
1.  IDENTIFY LOW-RISK PATIENTS CHA2DS2-VASc 0(m), 1(f) 
where no antithrombotic therapy is recommended.
2.  OFFER STROKE PREVENTION IF ≥1 non-sex stroke risk 
factor; Assess bleeding risk, address modifi able bleeding 
risk factors.
3.  CHOOSE OAC (a NOAC or VKA with well-managed TTR).
B = Better symptom management
1. Assess symptoms, QoL and patient’s preferences.
2. Optimise rate control.
3.  Consider a rhythm control strategy (Cardioversion, 
AADs, Ablation)
C =  Comorbidities and cardiovascular risk factor 
optimisation
Comorbidities and CV risk factors (HTN, HF, DM, CAD, 
OSA, etc.)
Lifestyle changes (obesity reduction, regular exercise and 
reduction of alcohol use, etc.)
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tent AF CA at 12 months (59%).(67) The STAR mapping sys-
tem (Figure 3) presented its feasibility clinical trial of 35 patients 
showing freedom from AF after persistent AF CA guided by 
STAR of 80% at 18 months.(68) It remains to be seen whether 
any of these make it to widespread clinical use.
Energy sources
High power short-duration RF may make point-by-point AF CA 
faster and, at least so far, not being associated with worse 
outcomes.(63)  Electroporation is also showing promise as a 
novel energy source that is highly effective with low complica-
tion rates.(69) The use of radiotherapy to treat intractable VT is 
an exciting innovation, showing promising results in a small 
prospective study of 19 patients.(70)
Guidelines and consensus statements
A number of guidelines have been published this year and 
while these are useful reviews of the literature, the tempta-
tion to accept them as dogma has to be resisted, given that 
they are often drive by consensus of a well-intentioned writing 
group rather than hard data. The CA of ventricular arrhythmia 
(VA) guideline suggests that programmed electrical stimulation 
may come back into fashion as a method for prognostic pre-
diction, this time in patients with frequent PVCs and structural 
heart disease, and also recommends use of ICE for VA abla-
tion, although much of the world does not use ICE without 
any apparent compromise to their outcomes.(71) The sex differ-
ences in arrhythmia consensus highlighted that although out-




This has been an exciting year in arrhythmogenic cardiomyo-
pathy (ACM). There are major publications to be aware of. 
The first is the Heart Rhythm Society Consensus Document 
on Arrhythmogenic Cardiomyopathy.(73) This document, which 
was led by McKenna and Towbin, redefines ACM as a condi-
tion that presents with symptomatic and/or asymptomatic 
arrhythmias in association with some degree of cardiac dys-
function. This “big tent” approach includes classic ARVC, 
the more recently described arrhythmogenic left ventricular 
cardiomyopathy, as well as other subgroups of patients. Included 
within ACM are sarcoidosis, Chagas disease, myocarditis, and a 
large number of inherited cardiomyopathies. This is a com-
prehensive and provocative article that is important to be 
aware of. One of the writing group’s goals was to encourage 
having patients present with arrhythmias and a cardiomyo-
pathy to a specialised centre that performs comprehensive 
ARRHYTHMIAS AND PACING
FIGURE 3: Ai - STAR map in an anterior-posterior view that shows an ESA (highlighted by the number (1) mapped to the anterior wall at 
the base of the LA appendage. Aii - Ablation here as demonstrated on a CARTO map in an anterior-posterior view resulted in Aiii - AF cycle 
length slowing from 152ms - 193ms, as measured from the LA appendage electrograms. Further cluster lesions at this ESA also intermittently 
organised CS activation. Bi - STAR map in a tilted posterior-anterior view that shows a further ESA (highlighted by the number (2) mapped to 
the posterior-inferior wall. Bii - Ablation here as shown on the CARTO maps in a similar view resulted in Biii - AF termination to AT as shown 































evaluation, arranges for genetic testing, and determines a 
patient’s arrhythmic risk and need for an ICD.(74)
Another important publication was authored by Cadrin-
Tourigny,  et al.(74)  Through the combined efforts of 5 inter-
national ARVC registries, an ARVC risk calculator was 
developed to help estimate arrhythmic risk and inform deci-
sions regarding ICD implantation (www.ARVCrisk.com). More 
than 500 ARVC patients from 5 registries in North America 
and Europe were enrolled. During 5 years of follow-up, 28% 
experienced sustained VT, sudden death, or received an 
appropriate ICD therapy. A prediction model to estimate 
annual arrhythmic risk was developed (Figure 4). The variables 
at baseline included in the model are recent syncope, age, 
gender, non-sustained VT, the number of PVCs in 24 hours, 
and right ventricular ejection fraction. Furthermore, a final 
paper by Chatterjee, et al.(75)  investigated the diagnostic value 
of an anti-Desmoglein-2 antibody in diagnosing ARVC. An 
antibody to DSG-2 was identified in 12/12 and 25/25 ARVC 
cohorts and 7/8 borderline subjects. The antibody was absent 
in 11/12 and 20/20 control cohorts. The authors concluded 
that anti-DSG-2 antibodies are a sensitive and specific marker 
for ARVC. Before this test can be used clinically, it will need to 
be tested in more controlled populations, including those with 
cardiac sarcoidosis.
Cardiac arrest
Sondergaard,  et al.(76)  examined the use of bystander CPR 
among patients who experienced out of hospital cardiac arrest 
in Denmark. More than three-fourths of cardiac arrests 
occurred in residential locations. Bystander CPR increased 
between 2001 and 2004 from 36% - 84% in public locations 
and from 16% - 61% in residential locations. Not surprisingly, 
the increased use of CPR resulted in an increased 30-day 
survival from 6% - 25% for arrests in public locations and from 
3% - 10% in residential locations.
CARDIAC DEVICES
What is the evidence behind current guideline recommenda-
tions for primary prevention ICD implantation in our present 
day and age? Can patient populations, background therapies 
and treatment algorithms, particular in heart failure, and under-
lying trials conducted well over a decade ago be extrapolated 
to current daily clinical practice? (Figure 5).(77) According to a 
large analysis from the French-British-Swedish-Czech CRT 
Network, death due to progressive heart failure remains the 
leading cause of death for most patients.(78) Moreover, increasing 
evidence indicates left ventricular (LV) remodelling as a main 
driver or arrhythmogenic events leading to sudden cardiac 
death (SCD), which may be reduced by modalities aimed at 
preventing (or even reversing) these processes, i.e. neuro-
hormonal blockade and cardiac resynchronisation therapy 
FIGURE 4: Prediction of sustained ventricular 
arrhythmia in arrhythmogenic right ventricular 
dysplasia/cardiomyopathy.
ARVC = arrhythmogenic right ventricular dysplasia/cardiomyopathy, inv. = inversion, 
PVC = premature ventricular complex, RVEF = right ventricular ejection fraction, 
VT = ventricular tachycardia.(74)
Prediction of sustained ventricular 
arrhythmia in ARVC
Sex x  0.49
Age x -0.022
Recent syncope x 0.66
Non-sustained VT x 0.81
Ln (24h PVC count) x 0.17
Leads with T-wave inv. x 0.11
RVEF x -0.025
Model for 5-year risk prediction
+
1 - 0.802exp(     ) = 5-year risk
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<5%            5% - 15%            15% - 25%
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5-year event-free survival (n = 528)
Per predicted risk group
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(CRT).(79)  These concepts and findings call into question the 
validity of the available randomised clinical trial evidence 
underlying current recommendations for primary prevention 
ICD implantation in heart failure patients. On a conceptual 
level, they additionally raise the question if trials should gener-
ally come with a “due date”, after which they would require 
re-validation. On the flipside, however, device therapies have 
advanced over the last decades, including better algorithms to 
detect ventricular arrhythmias and to prevent inadequate 
shocks, as well as the development of extravascular systems 
such as the S-ICD and the extravascular (EV-) ICD.(80) Indeed, 
even entirely leadless CRT systems appear to be feasible.(81) 
If proven safe and effective in the (ongoing) large RCTs, 
these novel modalities will come with a substantially reduced 
system-related morbidity, which may again tip the scale towards 
device-based SCD prevention. Indeed, inadequate shocks, as 
well as infections, remain the most devastating complications of 
current ICD systems, which come along with a substantial 
impact on quality of life, morbidity, and mortality.(82)
In addition, better means of risk prediction for SCD above and 
beyond left ventricular ejection fraction (LVEF) are desperately 
needed in order to better protect those patients who need it 
(and prevent those who do not from unnecessary device 
implantation). One such risk prediction model for patients 
post-myocardial infarction with preserved LVEF has recently 
been put forward using electrocardiographic non-invasive risk 
factors (PVCs, non-sustained VT, late potentials, prolonged 
QTc, increased T-wave alternans, reduced heart rate variability, 
and abnormal deceleration capacity with abnormal turbulence), 
ARRHYTHMIAS AND PACING
FIGURE 5: Two-year cause-specific mortality and non-fatal vascular events for patients with cardiovascular disease 
according to New York Heart Association (NYHA) class.
Numbers and proportions are a conceptual representation of absolute and relative risk and are not strictly evidence-based. Note that for 
patients in New York Heart Association Class 4, interventions for sudden arrhythmic death may be ineffective or fail to lead to a meaningful 
prolongation of life because the patient is likely to die soon of worsening heart failure.









































CRD 0 0 3 16 9 32 27 54
TSAD <1 <1 1 5 6 21 12 24
RSAD 2 17 5 26 3 11 1 2
SVD 2 17 3 16 4 14 5 10
NFVE 4 33 3 16 2 7 1 2
Non-CVD 4 33 4 21 4 14 4 8
CRD: Congestion-related death (heart failure, chest infection, multi-organ failure, etc.)
TSAD: Terminal sudden arrhythmic death RSAD: Resuscitatable SAD SVD: Sudden vascular death
NFVE: Non-fatal vascular event Non-CVD: Non-cardiovascular death
CRD = congestion-related death, otherwise called death due to worsening heart failure, NFVE = non-fatal vascular event (e.g. myocardial infarction and stroke; note that events are 
more likely to be suddenly fatal as heart failure progresses), Non-CVD = non-cardiovascular death, RSAD = resuscitatable sudden arrhythmic death, SVD = sudden vascular death, 













combined with programmed ventricular stimulation.(83)  The 
algorithm yielded an excellent sensitivity and negative predic-
tive value (arguably the most important parameter) of 100%, 
as well as a specificity of 93.8%; on the downside, positive 
predictive value was only 22%. Modern imaging modalities 
such as MRI may further yield added value in identifying patients 
at increased risk of ventricular arrhythmias who may benefit 
from ICD implantation.(84)  Similar algorithms are being devel-
oped also for rarer disease entities such as arrhythmogenic right 
ventricular cardiomyopathy (ARVC).(74)  If proven positive in 
randomised clinical outcome trials, these concepts may move 
the field closer to venturing beyond the current (suboptimal) 
standard of LVEF for risk stratification. Until such outcome trials 
are available, however, it may be prudent to stick to the 
currently available evidence and guideline recommendations; 
at the same time, recruitment into ongoing trials is encouraged 
in order to accelerate the generation of high-level evidence that 
may potentially alter current clinical practice.
Cardiac resynchronisation therapy remains an important treat-
ment modality for heart failure patients to induce reverse LV 
remodelling and to improve morbidity and mortality. However, 
the rate of so-called “non-responders” remains in the order of 
20% - 30%, depending on definitions and cut-offs.(85)  The 
MORE-CRT MPP trial investigated the effect of stimulating the 
LV from 2 sites instead of 1 to reduce the number of non-
responders.(86) Five hundred and forty-four patients classified as 
non-responders (defined as an LV end-systolic volume reduc-
tion by <15%) 6 months after CRT implantation were ran-
domised to receive the “Multipoint”TM algorithm turned on 
(MPP ON) or off (standard of care group). While the conversion 
rate to “responders” was no different between the 2 groups 
(31.8% vs. 33.8%), patients in the MPP group programmed 
to a wide electrode distance were significantly more likely 
to convert to responders than those programmed to other 
vector combinations (45.6% vs. 26.2%, p = 0.006).(86) Although 
interesting and biologically plausible, these findings have to 
be viewed as hypothesis-generating in view of the negative 
primary endpoint.
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